Highest-materiality recent filing
Net loss $62.5M ($1.04 diluted EPS) in Q2 2026 vs net loss $27.2M ($0.46) in Q2 2025; operating loss $62.4M.
Vanda Q1 net loss widens to $0.82/share; raises FY2026 revenue guidance on NEREUS launch
Fanapt net product sales $29.6M (+26% YoY); total prescriptions +32%, new-to-brand +76%.
Bysanti (milsaperidone) approved for acute manic/mixed episodes of bipolar I disorder and schizophrenia in adults.
Vanda FY2025: Fanapt sales +24% to $117.3M; net loss $220.5M; guides 2026 rev $230-260M
Fanapt net product sales $117.3M (+24% YoY); total revenues $216.1M (+9%); total prescriptions +28%, NBRx +149%.
FDA rejects Vanda's HETLIOZ sNDA for jet lag disorder after expedited re-review
FDA concluded sNDA cannot be approved in current form, citing phase advance protocols not sufficiently analogous to actual jet travel.
FDA approved NEREUS (tradipitant) on Dec 30, 2025 for prevention of vomiting induced by motion; first new drug class for motion sickness in >40 years.
FDA lifts partial clinical hold on Vanda's tradipitant for motion sickness
FDA lifted partial clinical hold on protocol VP-VLY-686-3403, removing the 90-dose cap on tradipitant studies.
Vanda Q3 revenue up 18% to $56.3M but net loss widens to $22.6M; guidance lowered
Total net product sales $56.3M (+18% YoY): Fanapt $31.2M (+31%), HETLIOZ $18.0M (+1%), PONVORY $7.0M (+20%).
Vanda reaches FDA framework to resolve disputes on HETLIOZ and tradipitant
FDA expedited re-review of tradipitant clinical hold by Nov 26, 2025; PDUFA date Dec 30, 2025.
Vanda Q2 net loss widens to $27.2M; Fanapt sales up 27% to $29.3M
Fanapt net product sales $29.3M (+27% YoY); HETLIOZ $16.2M (-13%), PONVORY $7.1M (-18%).
Vanda Q1 net loss widens to $29.5M; Fanapt sales up 14% but PONVORY down 18%
Net product sales $50.0M (+5% YoY); net loss $29.5M vs $4.1M loss a year ago.
FDA accepted for filing Vanda's NDA for tradipitant to treat motion sickness; PDUFA target date set for December 30, 2025.
Vanda Q4 2024 revenue $53.2M (+17% YoY); guides 2025 rev $210-250M
Q4 2024 net loss $4.9M vs $2.4M loss in Q4 2023; Fanapt sales $26.6M (+18% YoY).
Vanda files NDA for tradipitant to treat motion sickness
Vanda disclosed via 8-K that it filed a New Drug Application for tradipitant for motion sickness.
Vanda Q3 2024 revenue up 23% to $47.7M; guidance raised; net loss $5.3M
Q3 total net product sales $47.7M (+23% YoY); Fanapt $23.9M (+12%), HETLIOZ $17.9M (+2%), PONVORY $5.9M (-32% QoQ).
Vanda rejects Cycle Group's $8.00/share acquisition proposal as undervaluing company
Board unanimously determined second unsolicited proposal from Cycle Group not in best interests; terms identical to earlier May bid.
FDA issues Complete Response Letter declining Vanda's tradipitant NDA for gastroparesis
FDA declined to approve tradipitant for gastroparesis on Sept 18, 2024; issued CRL citing need for additional studies.
Vanda Q2 2024 revenue $50.5M (+10% YoY); net loss $4.5M; Fanapt bipolar launch underway
Q2 2024 total revenues $50.5M (up 10% YoY); net loss $4.5M vs net income $1.5M in Q2 2023.
Vanda Board rejects two unsolicited takeover proposals, citing undervaluation
Cycle Group bid $8.00/share cash; Future Pak offered $8.50-$9.00/share plus CVRs.
Future Pak LLC proposes $8.50-$9.00 per share cash plus Contingent Value Rights for Vanda Pharmaceuticals.
Vanda receives unsolicited acquisition proposal from Cycle Group at $8.00/share
Cycle Group Holdings Ltd. made an unsolicited, non-binding proposal to acquire Vanda for $8.00 per share in cash.
Vanda Pharmaceuticals Board Rejects Revised Unsolicited Takeover Bid from Future Pak
Future Pak offered $7.25-$7.75 per share in cash plus Contingent Value Rights to acquire Vanda.
Vanda Q1 revenue $47.5M, net loss $4.1M; Fanapt bipolar approval, PONVORY launch in Q3
Net loss $4.1M (diluted EPS -$0.07) vs net income $3.3M ($0.06) in Q1 2023; revenue $47.5M, -24% YoY.
Vanda receives revised unsolicited takeover proposal from Future Pak at $7.25-$7.75/share plus CVRs
Revised proposal of $7.25-$7.75 per share in cash plus Contingent Value Rights (CVRs).
Vanda adopts limited-duration rights plan; rejects Future Pak's $7.25-$7.75/share bid
Board adopted a one-year stockholder rights plan effective April 17, 2024, triggered at 10% beneficial ownership.
Vanda's Fanapt receives FDA approval for bipolar I disorder indication
FDA approved Fanapt (iloperidone) on April 2, 2024 for acute treatment of manic or mixed episodes in bipolar I disorder in adults.
FDA issues Complete Response Letter for Vanda's HETLIOZ insomnia sNDA
Received CRL on March 4, 2024 for HETLIOZ (tasimelteon) to treat insomnia with sleep initiation difficulties.
Purchase price $100M for U.S./Canadian rights of PONVORY (ponesimod) from Johnson & Johnson.
Vanda reports FY2023 revenue $192.6M (-24% YoY); Q4 net loss $2.4M; PDUFA dates in 2024
Full year 2023 net product sales $192.6M, down 24% from $254.4M; Q4 net loss $2.4M vs income $6.9M in Q4 2022.
FDA identifies deficiencies in Vanda's sNDA for HETLIOZ insomnia; Vanda alleges FDCA violation
FDA notified Vanda on Feb 4, 2024 of deficiencies in sNDA for HETLIOZ (tasimelteon) for insomnia; no details disclosed.
Vanda acquires U.S. and Canadian rights to PONVORY for $100M upfront
Acquired exclusive U.S. and Canadian rights to PONVORY (ponesimod), a once-daily oral S1P1R modulator for relapsing multiple sclerosis.
Vanda Q3 net product sales $38.8M, down 41% YoY; generic Hetlioz hurts; two PDUFA dates in H1 2024
Q3 2023 net product sales $38.8M vs $65.3M YoY; net income $0.1M ($0.00 EPS) vs $3.3M ($0.06) prior year.
Vanda's petition for rehearing on patent invalidation denied by Federal Circuit
Federal Circuit denied Vanda's rehearing petition on August 16, 2023, affirming invalidity of four patents.
Vanda Q2 revenue drops 28% to $46.1M on HETLIOZ generic erosion
HETLIOZ net sales $22.0M, down 47% YoY due to at-risk generic launch.
On March 15, 2023, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc. (the “Company”) expanded the size of the Board from five to six members, effective immediately and appointed Tage Honoré, Ph.D., D.Sc., as a director of the Company to fill the vacancy created by the expansion.
Mr. Jones resigned as the Company’s Chief Corporate Affairs and Communications Officer effective as of October 26, 2021.
H. Thomas Watkins notified the Board that he would resign from the Board as a Class I director effective as of the Company’s 2022 Annual Meeting of Stockholders
On October 6, 2021, Aranthan “AJ” Jones II notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Corporate Affairs and Communications Officer, effective as of October 26, 2021, in order to join a U.S.-based, publicly traded company outside of the biopharmaceutical sector.
Max materiality 0.85 · Median 0.70 · Most common event earnings